NCT02354534View on ClinicalTrials.gov

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

November 6, 2018

Conditions
Cervical Intraepithelial Neoplasia Grade 2/3High-risk HPV (Any Strain)
Interventions
DRUG

Artesunate Suppositories

Trial Locations (3)

21204

Greater Baltimore Medical Center, Towson

21205

Johns Hopkins Outpatient Center, Baltimore

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors
All Listed Sponsors
collaborator

Frantz Viral Therapeutics, LLC

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER